Marchex is a thinly covered micro-cap. The only clearly current, attributable analyst price target found across data providers is $4.00 from Northland Securities, which reiterated a Buy rating in August 2026. A single target cannot form a meaningful "analyst consensus," so the stock forecast framework here instead uses the fallback approach: a realistic price objective resting on identifiable public discussion.
That objective is $2.00, the stock's 52-week high and a widely referenced resistance level (Yahoo Finance lists the 52-week range at roughly $1.15 to $2.00). As a round-number psychological level and a prior peak, $2.00 is a credible technical milestone rather than a fabricated forecast. It is at least 10% above the current price yet not unrealistically distant, unlike the $4.00 analyst figure, which represents a 200%-plus move.
At a recent price near $1.30, Marchex carries a market capitalization of roughly $57.6 million. Reaching $2.00 would require a gain of about 54%, which is a substantial move for a stock that has spent much of its recent range between $1.15 and $2.00.
The potential path runs through execution on the Archenia acquisition, which closed on July 1, 2026. Marchex reported Q2 2026 revenue of $11.0 million, modestly higher sequentially but down year over year, and guided Q3 revenue to $16.0–$16.5 million with adjusted EBITDA of $2.3–$2.5 million as Archenia's first full quarter flows through. Management has framed a long-term ambition to grow toward $100 million in annual revenue and a "Rule of 30–40" profile (combining revenue growth and adjusted EBITDA margin). Converting early pilot and cross-sell wins into recurring, scalable revenue is the crux of any re-rating toward $2.00.
The 52-week range of approximately $1.15 to $2.00 defines the durable structure. The $2.00 area is the principal resistance level — a prior peak and round number — while $1.15 marks the key support level below. The stock has recently traded in the lower half of this range and below its 200-day moving average (cited near $1.58 in recent commentary), meaning a sustained move toward $2.00 would first require reclaiming that intermediate zone and then clearing the upper boundary of the range.
The $2.00 milestone is a technical objective without a formal research horizon; the single $4.00 analyst target typically reflects a roughly 12-month view. The most important near-term catalyst is the Q3 2026 earnings report, expected in early November 2026, when management plans to provide Q4 guidance and an initial 2027 outlook. Investors should watch revenue versus the $16.0–$16.5 million guide, adjusted EBITDA versus $2.3–$2.5 million, cash trends, and whether the named customer pilots convert into contracted, recurring deployments. Any analyst target changes or new coverage would also matter, given how little coverage the stock has.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. For a thinly traded, event-driven name like Marchex, these signals can help traders surface shifting momentum, track positions, and spot emerging trends more efficiently than manual scanning. Traders looking to stay ahead of developing opportunities may find the AI Daily Buy/Sell Signals a useful complement to their own research.
Whether Marchex (MCHX) can reach $2.00 depends on the company delivering on the Archenia integration and converting early cross-sell wins into durable, recurring revenue. The required 54% move is substantial, and the objective is a technical milestone rather than a consensus forecast — the one attributable analyst target of $4.00 is far more ambitious and rests on a single firm's view. The step-change in revenue guidance and a low valuation provide a credible foundation for the bullish case, while customer concentration, a thin cash position, and execution risk remain the principal obstacles. The Q3 2026 report and its 2027 outlook are the clearest next test.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that MCHX and EVC have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MCHX and EVC's prices will move in lockstep.
| Ticker / NAME | Correlation To MCHX | 1D Price Change % | ||
|---|---|---|---|---|
| MCHX | 100% | +5.26% | ||
| EVC - MCHX | 33% Poorly correlated | -2.04% | ||
| STGW - MCHX | 20% Poorly correlated | -1.91% | ||
| BOC - MCHX | 20% Poorly correlated | -0.58% | ||
| NCMI - MCHX | 20% Poorly correlated | -2.41% | ||
| ABLV - MCHX | 20% Poorly correlated | +0.84% | ||
More | ||||